|1.||Bertini, Riccardo: 7 articles (09/2007 - 08/2004)|
|2.||Allegretti, Marcello: 5 articles (04/2015 - 08/2004)|
|3.||Colotta, Francesco: 4 articles (06/2005 - 08/2004)|
|4.||Cavalieri, Barbara: 3 articles (09/2007 - 08/2004)|
|5.||Bizzarri, Cinzia: 3 articles (08/2007 - 08/2004)|
|6.||Locati, Massimo: 3 articles (08/2007 - 08/2004)|
|7.||Galliera, Emanuela: 3 articles (08/2007 - 08/2004)|
|8.||Villa, Pia: 3 articles (03/2007 - 08/2004)|
|9.||Ghezzi, Pietro: 3 articles (03/2007 - 08/2004)|
|10.||Di Bitondo, Rosa: 3 articles (03/2007 - 08/2004)|
04/01/2015 - "Reparixin and ladarixin, noncompetitive allosteric inhibitors, were used to pharmacologically blockade CXCR1/2. Transient blockade of said receptors was effective in preventing inflammation-mediated damage in MLD-STZ and in preventing and reversing diabetes in NOD mice. "
03/01/2007 - "Reparixin, administered for 1 to 3 days, 3.5 to 6 h after MCAO, ameliorates neurological function recovery and inhibits long-term inflammation. "
01/01/2007 - "In conclusion, our study showed that reparixin was safe but had no impact on endotoxin induced inflammation. "
01/01/2011 - "Prophylactic treatment with repertaxin had no effect on acute inflammation or liver injury. "
01/01/2007 - "We therefore tested the effects of reparixin on humoral and cellular parameters in LPS-induced acute systemic inflammation. "
|2.||Acute Lung Injury
10/01/2008 - "Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury in mice."
02/03/2015 - "One aim of this study was to evaluate whether a low-dose of DEX in combination with the antioxidant N-acetyl cysteine (NAC) and if different treatments (Triptolide, Reparixin and Rolipram) administered 1h after Cl2-exposure could improve protection against acute lung injury in Cl2-exposed mice. "
03/01/2011 - "Both 7.5 and 15 mg kg(-1) Reparixin reduced development of autonomic dysreflexia 4 weeks post-SCI. The change in mean arterial pressure, induced by cutaneous or visceral stimulation, was reduced by 40-50%. "
03/01/2011 - "Histopathology and neurological outcomes were assessed by immunohistochemistry, locomotion scoring and cardiovascular measurement of autonomic dysreflexia 4 weeks post-SCI. Both 7.5 and 15 mg kg(-1) doses of Reparixin reduced levels of TNF-α and CINC-1 72 h post-SCI and decreased macrophage (CD68) content in the spinal cord lesion. "
03/01/2011 - "Acute treatment with 15 mg kg(-1) Reparixin reduces acute inflammation and is associated with minor improvements in motor function and a significant reduction in the severity of autonomic dysreflexia."
04/01/2015 - "Reparixin, a CXCR 1/2 antagonist, has been shown to mitigate ischaemia-reperfusion injury (IRI) in various organ systems in animals, but data in humans are scarce. "
06/30/2005 - "Among these, repertaxin (13) was selected as a clinical candidate drug for prevention of post-ischemia reperfusion injury."
09/01/2004 - "Thus, drugs, such as Repertaxin, developed to block the function of the CXCR2 receptor may be effective at preventing reperfusion injury in relevant clinical situations."
09/01/2004 - "Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury."
08/10/2004 - "Repertaxin is an effective inhibitor of polymorphonuclear cell recruitment in vivo and protects organs against reperfusion injury. "
01/01/2013 - "Pre-treatment with reparixin reduced the motor deficits observed in this model of ischemia and reperfusion. "
05/07/2005 - "Since the PMN infiltration and its inhibition by repertaxin were comparable in the two models we conclude that reperfusion induces PMN activation, and inhibition of CXCL8 by repertaxin might be of pharmacological interest in transient ischemia."
05/07/2005 - "In transient ischemia (90-min ischemia followed by reperfusion), repertaxin inhibited PMN infiltration by 54% and gave 44% protection from tissue damage. "
05/07/2005 - "In permanent ischemia repertaxin reduced PMN infiltration by 40% in the brain cortex but did not limit tissue damage. "
05/07/2005 - "Repertaxin (15 mg/kg) was administered systemically at the time of ischemia and every 2 h for four times. "
|4.||Interleukin-8 (Interleukin 8)
|6.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|7.||Interleukin-8A Receptors (Receptors, Interleukin 8A)
|9.||Conditioned Culture Media
|10.||Interleukin-6 (Interleukin 6)
|1.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
|4.||Heterologous Transplantation (Xenotransplantation)
|5.||Drug Therapy (Chemotherapy)